Fig. 7: IAMP29 treatment restricts the intracellular growth of NTMs in human and murine macrophages.
From: The inflammasome-activating poxvirus peptide IAMP29 promotes antimicrobial and anticancer responses
a The cytotoxicity of IAMP29 in PBMCs and monocytes was assessed via a CCK-8 assay. The cells were treated with IAMP29 (0.2, 1, 5, or 25 μg/mL for 24 h) after LPS or BCG pretreatment. b Intracellular survival of smooth strains of Mboll and Mabc in IAMP29-treated human primary MDMs after Mboll or Mabc infection (MOI = 1 for 2 h), as determined by a CFU assay. IL-1β (c) and TNF (d) concentrations in the supernatants of IAMP29-treated human MDMs. The cells were treated with IAMP29 (25 μg/mL for 18 h) after Mboll or Mabc infection (MOI = 1 for 2 h). e Western blots showing the levels of mature IL-1β and mature caspase-1 in culture supernatants (Sup.) and pro-IL-1β, pro-caspase-1, NLRP3, and ASC in cell lysates (Lys.) of Mboll- or Mabc-infected human MDMs treated with IAMP29 (25 μg/mL for 18 h). Intracellular survival of Mboll (f) and Mabc (g) in human MDMs with PKM2 knockdown after Mboll or Mabc infection (MOI = 1 for 2 h), as determined by a CFU assay. Intracellular survival of Mboll (h) and Mabc (i) in Mboll- or Mabc-infected murine BMDMs treated with IAMP29 (40 μg/mL for 18 h) after pretreatment with MitoTEMPO (1 and 10 μM for 2 h) or 2-DG (10 and 100 μM for 2 h), as determined by a CFU assay. Statistical analysis was conducted with an unpaired t-test with the Mann‒Whitney test or one-way ANOVA with Tukey’s multiple comparison test, and the results are presented as the means ± SDs. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. ns not significant.
